Calcifediol monohydrate
(Synonyms: 骨化二醇一水合物,25-hydroxy Vitamin D3 monohydrate) 目录号 : GC16720骨化二醇一水合物(25-羟基维生素 D3 一水合物)是维生素 D3 的主要循环代谢物,是一种有效的 VDR 抑制剂。
Cas No.:63283-36-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Calcifediol is a prehormone that is produced in the liver by hydroxylation of vitamin D3 (cholecalciferol) and is the best indicator of total vitamin D exposure [1].
The main circulating form of vitamin D, higher serum levels of calcifediol is associated with lower incidence rates of colon, breast, ovarian, renal, pancreatic, aggressive prostate and other cancers [2].
In bovine parathyroid cells, Calcifediol can reduce parathyroid hormone (PTH) secretion and mRNA synthesis [3]. In T-47D breast cancer cells, calcifediol mediated activation of VDR (the vitamin D receptor), which was associated with endocytosis of DBP (vitamin D binding protein). So T-47D breast cancer cells can rapidly internalize DBP [4].
In the pooled study included 616 colorectal adenoma cases and 770 controls, the association between circulating 25(OH)D3 and colorectal adenoma risk was estimated through multivariable logistic regression. The higher circulating 25(OH)D3 concentrations were significantly associated with lower colorectal adenoma risk [1].
References:
[1]. Fedirko V, Bostick RM, Goodman M, et al. Blood 25-hydroxyvitamin D3 concentrations and incident sporadic colorectal adenoma risk: a pooled case-control study. Am J Epidemiol, 2010, 172(5): 489-500.
[2]. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D for cancer prevention: global perspective. Ann Epidemiol, 2009, 19(7): 468-483.
[3]. Ritter CS, Armbrecht HJ, Slatopolsky E, et al. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int, 2006, 70(4): 654-659.
[4]. Rowling MJ, Kemmis CM, Taffany DA, et al. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr, 2006, 36(11): 2754-2759.
Cas No. | 63283-36-3 | SDF | |
别名 | 骨化二醇一水合物,25-hydroxy Vitamin D3 monohydrate | ||
化学名 | (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol;hydrate | ||
Canonical SMILES | CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C.O | ||
分子式 | C27H46O3 | 分子量 | 418.65 |
溶解度 | DMSO : 50 mg/mL (119.43 mM);Soluble in Chloroform | 储存条件 | Store at -20°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3886 mL | 11.9432 mL | 23.8863 mL |
5 mM | 0.4777 mL | 2.3886 mL | 4.7773 mL |
10 mM | 0.2389 mL | 1.1943 mL | 2.3886 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。